arrow
T

Toby M. Maher

imperial college london
H指数:94
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials

特发性肺纤维化的预后生物标志物:ISABELA临床试验的结果

2026-02-160
PRE
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)
2025-12-040
OAAI
Reply: The rationale for distinguishing RB-ILD and AMP

回复:区分RB-ILD和AMP的依据

2025-12-011
PRE
Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis

回复:细支气管中心性间质性肺炎是一个用于肺活检和胸部影像学模式的形态学术语,它并不是过敏性肺炎的替代术语。

2025-12-010
PRE
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement

Ryerson, C.J.; Adegunsoye, A.; Piciucchi, S.; Hariri, L.P.; Khor, Y.H.; Wijsenbeek, M.S.; Wells, A.U.; Sharma, A.; Cooper, W.A.; Antoniou, K.; et al. 间质性肺炎的国际多学科分类更新:ERS/ATS声明。Eur. Respir. J. 2025, 2500158. [Google Scholar] [CrossRef] [PubMed]

2025-12-0133
PRE
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

塔拉地吉用于特发性肺纤维化治疗的试验(ENV-IPF-101):一项多中心、随机、双盲、安慰剂对照的2a期临床试验

2025-09-300
PRE
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation

特发性肺纤维化患者中的罕见变异与生存:一项多中心、观察性队列研究及独立验证分析

2025-04-280
OA